FDA-to-APAC: Your US Regulatory Package Is Your APAC Head Start
For US companies with FDA 510(k) clearance, PMA approval, or De Novo authorization, entering APAC markets is significantly faster than starting from scratch. Singapore HSA, Japan PMDA, Korea MFDS, and Taiwan TFDA all offer reliance or abbreviated pathways for FDA-cleared devices — reducing technical review timelines by 40–60% compared to a full submission.
JNPMEDI APAC's US-to-APAC service starts with a regulatory gap analysis: we map your existing FDA technical file against each target APAC market's requirements, identify what additional data is needed, and build a coordinated regional submission plan. The result is a single, integrated dossier strategy that covers Singapore, Japan, Korea, Taiwan, and ASEAN under one vendor relationship.
For US pharma and biotech companies, our NDA-to-ACTD bridging service applies the same principle to pharmaceutical market access — adapting your FDA submission data for Singapore HSA, Korea MFDS, and other APAC regulatory authorities, while JNPMEDI APAC serves as your independent Marketing Authorization Holder across each market.
- FDA 510(k) / PMA / De Novo accepted as reference by HSA, PMDA, MFDS, TFDA
- JNPMEDI APAC serves as independent MAH in each target APAC market
- Single dossier strategy across all target markets — no parallel vendor management
- FDA-to-ACTD pharmaceutical bridging for Singapore, Korea, and ASEAN
- US office support for US-based clients throughout submission cycle
Indicative APAC Registration Timelines (FDA-Cleared Devices)
Using FDA clearance as reference — abbreviated / reliance pathways. Excludes deficiency response periods.
US-to-APAC: Integrated Services for US Healthcare Companies
FDA-to-APAC Regulatory Bridging
Gap analysis mapping your FDA technical file to each APAC target market. We identify what additional data is required, structure the cross-market dossier, and manage all submissions — Singapore, Japan, Korea, Taiwan, and ASEAN — under a coordinated timeline.
Independent MAH Across APAC
JNPMEDI APAC acts as your independent Marketing Authorization Holder in Singapore, Korea, and other APAC markets — keeping your registration structurally separate from distribution partners. No need to establish local subsidiaries before validating the market.
APAC CRO & Clinical Bridging
When APAC regulators require local clinical data or bridging studies, JNPMEDI APAC's in-house CRO capability handles Phase I–IV clinical operations across Singapore, Korea, and ASEAN — including protocol design, site management, and Maven Clinical Cloud data management.
Why JNPMEDI APAC for US Companies Entering APAC
Managing APAC expansion through separate local regulatory agencies in each country multiplies coordination overhead, cost, and risk. JNPMEDI APAC is the single point of contact for your entire APAC regulatory and commercial entry strategy — Singapore, Korea, Malaysia, Indonesia, Vietnam, Thailand, India, and the extended APAC network — under one platform.
US regulatory standards are globally respected. JNPMEDI APAC's FDA-to-APAC bridging service extracts maximum leverage from your existing FDA technical documentation — minimizing duplicated effort, accelerating submission preparation, and ensuring consistency across all target markets.
Singapore HSA registration is widely viewed as the entry point for APAC market access — and HSA approval provides significant leverage for Malaysia, Indonesia, Vietnam, Thailand, and India submissions. JNPMEDI APAC's Singapore-based headquarters makes us the natural APAC platform for US companies looking to build a systematic, scalable regional presence.
US Companies Entering APAC — FAQ
Yes — many APAC regulators accept FDA clearance as a primary reference, substantially reducing technical review requirements. Singapore HSA, Korea MFDS, Japan PMDA, Taiwan TFDA, Malaysia NPRA, and others all have some form of abbreviated or reliance pathway for FDA-cleared devices. The specific leverage varies by market and device class. JNPMEDI APAC maps your FDA clearance against each target market's pathway and builds the most efficient submission strategy.
No. JNPMEDI APAC acts as your local Marketing Authorization Holder (MAH) or Registrant in Singapore and coordinates equivalent arrangements in Korea and other markets. This means you can enter APAC markets without establishing local subsidiaries — reducing upfront investment while validating commercial traction before committing to in-country infrastructure.
Singapore is typically the recommended first entry point. HSA has a transparent, English-language regulatory process with well-defined timelines, and Singapore approval provides direct leverage for subsequent submissions in Malaysia, Indonesia, and Vietnam. It's also the APAC commercial hub — the right base for distribution relationships, clinical partnerships, and regional operations. JNPMEDI APAC is Singapore-headquartered and manages the full Singapore-first, APAC-wide expansion playbook.
With FDA clearance as a reference, Singapore HSA Abridged/Expedited review takes approximately 170–185 days from submission acceptance. Korea MFDS Class III abbreviated review runs approximately 180–270 days. Japan PMDA is longer — 12–18 months. Running submissions in parallel across markets (Singapore + Korea + Taiwan simultaneously) is our standard approach for US companies with time-sensitive launch targets, since timelines overlap rather than stack.